Drugs / MenB vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04707391 Background | Jan 2021 → May 2023 | meningococcal meningitis | GlaxoSmithKline | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MenB vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04707391 ↗ |
| Modality | Vaccine | “MenB vaccine” NCT04707391 ↗ |
| Route | Intramuscular | “MenB vaccine administered intramuscularly” NCT04707391 ↗ |